Cargando…

Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer

BACKGROUND: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Belbaraka, Rhizlane, Trédan, Olivier, Ray-Coquard, Isabelle, Chvetzoff, Giselle, Bajard, Agathe, Pérol, David, Ismaili, Nabil, Ismaili, Mohammed, Errihani, Hassan, Bachelot, Thomas, Rebattu, Paul
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904794/
https://www.ncbi.nlm.nih.gov/pubmed/20537187
http://dx.doi.org/10.1186/1756-0500-3-164
_version_ 1782183913887629312
author Belbaraka, Rhizlane
Trédan, Olivier
Ray-Coquard, Isabelle
Chvetzoff, Giselle
Bajard, Agathe
Pérol, David
Ismaili, Nabil
Ismaili, Mohammed
Errihani, Hassan
Bachelot, Thomas
Rebattu, Paul
author_facet Belbaraka, Rhizlane
Trédan, Olivier
Ray-Coquard, Isabelle
Chvetzoff, Giselle
Bajard, Agathe
Pérol, David
Ismaili, Nabil
Ismaili, Mohammed
Errihani, Hassan
Bachelot, Thomas
Rebattu, Paul
author_sort Belbaraka, Rhizlane
collection PubMed
description BACKGROUND: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic factors. In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified. FINDINGS: Forty-five patients that were previously treated for metastatic disease from 12/2000 to 11/2005 in the comprehensive cancer centre (Centre Léon Bérard). Clinical assessment and blood parameters were recorded and considered. Patient prognostic factors for overall survival (OS) with a 0.05-significance level in univariate analysis were entered in a multivariate Cox model for further analysis. Patients' median age was 58.5 years (range: 37 - 76). Sixty two percent of the patients were PS = 0 or 1. After inclusion, nine patients received second-line (22.5%), and two received third-line chemotherapy (5%). Univariate analysis showed that the factors associated with reduced OS were: PS > 2, weight loss >10%, more than one line of chemotherapy treatment and abnormal blood parameters (hemoglobin (Hb), platelet and neutrophils counts). Multiple regression analysis confirmed that PS > 2 and abnormal hemoglobin were independent predictors for low overall survival. According to the presence of none (33%), 1 (37%) and 2 (30%) prognostic factors, median OS were 12, 5 and 2 months respectively. CONCLUSION: From this prospective study, both PS and anemia were found as independent determinants of survival, we found that both PS and anemia were independent determinants of survival. The combination of poor PS and anemia is an effective strategy to predict survival in the case of patients with metastatic NSCLC receiving further treatment after the first line.
format Text
id pubmed-2904794
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29047942010-07-16 Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer Belbaraka, Rhizlane Trédan, Olivier Ray-Coquard, Isabelle Chvetzoff, Giselle Bajard, Agathe Pérol, David Ismaili, Nabil Ismaili, Mohammed Errihani, Hassan Bachelot, Thomas Rebattu, Paul BMC Res Notes Short Report BACKGROUND: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic factors. In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified. FINDINGS: Forty-five patients that were previously treated for metastatic disease from 12/2000 to 11/2005 in the comprehensive cancer centre (Centre Léon Bérard). Clinical assessment and blood parameters were recorded and considered. Patient prognostic factors for overall survival (OS) with a 0.05-significance level in univariate analysis were entered in a multivariate Cox model for further analysis. Patients' median age was 58.5 years (range: 37 - 76). Sixty two percent of the patients were PS = 0 or 1. After inclusion, nine patients received second-line (22.5%), and two received third-line chemotherapy (5%). Univariate analysis showed that the factors associated with reduced OS were: PS > 2, weight loss >10%, more than one line of chemotherapy treatment and abnormal blood parameters (hemoglobin (Hb), platelet and neutrophils counts). Multiple regression analysis confirmed that PS > 2 and abnormal hemoglobin were independent predictors for low overall survival. According to the presence of none (33%), 1 (37%) and 2 (30%) prognostic factors, median OS were 12, 5 and 2 months respectively. CONCLUSION: From this prospective study, both PS and anemia were found as independent determinants of survival, we found that both PS and anemia were independent determinants of survival. The combination of poor PS and anemia is an effective strategy to predict survival in the case of patients with metastatic NSCLC receiving further treatment after the first line. BioMed Central 2010-06-10 /pmc/articles/PMC2904794/ /pubmed/20537187 http://dx.doi.org/10.1186/1756-0500-3-164 Text en Copyright ©2010 Belbaraka et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Belbaraka, Rhizlane
Trédan, Olivier
Ray-Coquard, Isabelle
Chvetzoff, Giselle
Bajard, Agathe
Pérol, David
Ismaili, Nabil
Ismaili, Mohammed
Errihani, Hassan
Bachelot, Thomas
Rebattu, Paul
Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
title Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
title_full Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
title_fullStr Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
title_full_unstemmed Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
title_short Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
title_sort factors of interrupting chemotherapy in patients with advanced non-small-cell lung cancer
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904794/
https://www.ncbi.nlm.nih.gov/pubmed/20537187
http://dx.doi.org/10.1186/1756-0500-3-164
work_keys_str_mv AT belbarakarhizlane factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT tredanolivier factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT raycoquardisabelle factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT chvetzoffgiselle factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT bajardagathe factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT peroldavid factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT ismailinabil factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT ismailimohammed factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT errihanihassan factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT bachelotthomas factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer
AT rebattupaul factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer